<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250730</url>
  </required_header>
  <id_info>
    <org_study_id>A8081022</org_study_id>
    <nct_id>NCT01250730</nct_id>
  </id_info>
  <brief_title>A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066</brief_title>
  <official_title>A Phase 1, Open Label, Dose Escalation, Single Oral Dose Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics of single doses of
      PF-02341066 (150, 250, and 400 mg) in the fasted condition in Japanese healthy male
      volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics of single doses of
      PF-02341066 (150, 250, and 400 mg) in the fasted condition in Japanese healthy male
      volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>AUC(0-inf) of crizotinib is estimated from the crizotinib concentration. It is obtained from AUClast plus (Clast/kel).
AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration.
Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Crizotinib</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Crizotinib</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of Crizotinib</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (t1/2) of Crizotinib</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>t1/2 of crizotinib is the time measured for the plasma concentration to decrease by one half. It is obtained from a Loge(2)/kel.
Kel = terminal phase elimination rate constant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of Crizotinib</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>CL/F of crizotinib is obtained from a Dose per AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Crizotinib</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Vz/F of crizotinib is obtained from a Dose / (AUCinf *kel).
Kel = terminal phase elimination rate constant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Normalized AUC(0-inf) of Crizotinib</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Dose normalized (to 150 mg dose) AUC(0-inf) is obtained from AUC(0-inf) / (Dose/150).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Normalized AUClast of Crizotinib</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Dose normalized (to 150 mg dose) AUClast is obtained from AUClast / (Dose/150).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Normalized Cmax of Crizotinib</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Dose normalized (to 150 mg dose) Cmax is obtained from Cmax / (Dose/150).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUC0-inf) of Plasma Active Metabolite (PF-06260182)</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>AUC(0-inf) of PF-06260182 is estimated from the PF-06260182 concentration. It is obtained from AUClast plus (Clast/kel).
AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration.
Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Plasma Active Metabolite (PF-06260182)</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Plasma Active Metabolite (PF-06260182)</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of Plasma Active Metabolite (PF-06260182)</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite to Parent Ratio AUC(0-inf)</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>The metabolic ratio (MR) is calculated by first converting the AUC(0-inf) for both crizotinib and metabolite (PF-06260182) from mass units to molar units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite to Parent Ratio AUClast</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>The metabolic ratio (MR) is calculated by first converting the AUClast for both crizotinib and metabolite (PF-06260182) from mass units to molar units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite to Parent Ratio Cmax</measure>
    <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>The metabolic ratio (MR) is calculated by first converting the Cmax for both crizotinib and metabolite (PF-06260182) from mass units to molar units.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study will consist of three cohorts: PF-02341066 150 mg treatment group (n = 6), PF-02341066 250 mg treatment group (n = 6) and PF-02341066 400 mg treatment group (n = 6).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-02341066</intervention_name>
    <description>Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.</description>
    <arm_group_label>1.0</arm_group_label>
    <other_name>Not Specified</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-02341066</intervention_name>
    <description>Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.</description>
    <arm_group_label>1.0</arm_group_label>
    <other_name>Not Specified</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-02341066</intervention_name>
    <description>Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.</description>
    <arm_group_label>1.0</arm_group_label>
    <other_name>Not Specified</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects, inclusive (Healthy is defined as no clinically relevant
             abnormalities identified by a detailed medical history, full physical examination,
             including blood pressure and pulse rate measurement, 12-lead ECG and clinical
             laboratory tests).

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg

        Exclusion Criteria:

          -  Subjects who are smoking,

          -  Subjects with evidence of disease,

          -  Subjects with conditions affecting absorption,

          -  Subjects with treatment with other investigational drug within 30 days,

          -  Subjects with history of regular alcohol consumption,

          -  Subjects with use of prescription, nonprescription drugs and dietary supplement within
             28 days,

          -  Subjects with blood donation of approximately 400 mL within 3 months or 200 mL within
             1 month prior to dosing
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8081022&amp;StudyName=A%20Study%20In%20Japanese%20Healthy%20Male%20Volunteers%20To%20Investigate%20The%20Safety%2C%20Tolerability%20And%20Pharmacokinetics%20Of%20PF-02341066%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <results_first_submitted>October 20, 2011</results_first_submitted>
  <results_first_submitted_qc>October 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2011</results_first_posted>
  <last_update_submitted>October 20, 2011</last_update_submitted>
  <last_update_submitted_qc>October 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK profile in Japanese healthy male volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Twelve healthy subjects were assigned to open-label crizotinib treatment in either the 150 mg cohort (6 subjects) or 250 mg cohort (6 subjects).
After the completion of assessment of safety at both 150 mg and 250 mg cohorts, the 400 mg cohort, the highest dose level in this study, was started.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Crizotinib 150 mg</title>
          <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
        </group>
        <group group_id="P2">
          <title>Crizotinib 250 mg</title>
          <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
        </group>
        <group group_id="P3">
          <title>Crizotinib 400 mg</title>
          <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Crizotinib 150 mg</title>
          <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
        </group>
        <group group_id="B2">
          <title>Crizotinib 250 mg</title>
          <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
        </group>
        <group group_id="B3">
          <title>Crizotinib 400 mg</title>
          <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib</title>
        <description>AUC(0-inf) of crizotinib is estimated from the crizotinib concentration. It is obtained from AUClast plus (Clast/kel).
AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration.
Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib</title>
          <description>AUC(0-inf) of crizotinib is estimated from the crizotinib concentration. It is obtained from AUClast plus (Clast/kel).
AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration.
Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.</description>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1423" spread="471.52"/>
                    <measurement group_id="O2" value="3806" spread="1313.2"/>
                    <measurement group_id="O3" value="6569" spread="2098.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Crizotinib</title>
        <description>AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Crizotinib</title>
          <description>AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.</description>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1339" spread="472.66"/>
                    <measurement group_id="O2" value="3732" spread="1312.4"/>
                    <measurement group_id="O3" value="6386" spread="2084.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Crizotinib</title>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Crizotinib</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.54" spread="25.570"/>
                    <measurement group_id="O2" value="155.6" spread="50.694"/>
                    <measurement group_id="O3" value="235.8" spread="60.988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Cmax (Tmax) of Crizotinib</title>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) of Crizotinib</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="5.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="5.00" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="5.00" lower_limit="5.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life (t1/2) of Crizotinib</title>
        <description>t1/2 of crizotinib is the time measured for the plasma concentration to decrease by one half. It is obtained from a Loge(2)/kel.
Kel = terminal phase elimination rate constant</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (t1/2) of Crizotinib</title>
          <description>t1/2 of crizotinib is the time measured for the plasma concentration to decrease by one half. It is obtained from a Loge(2)/kel.
Kel = terminal phase elimination rate constant</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.08" spread="6.7683"/>
                    <measurement group_id="O2" value="29.90" spread="3.9945"/>
                    <measurement group_id="O3" value="29.13" spread="3.5753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance (CL/F) of Crizotinib</title>
        <description>CL/F of crizotinib is obtained from a Dose per AUCinf.</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F) of Crizotinib</title>
          <description>CL/F of crizotinib is obtained from a Dose per AUCinf.</description>
          <units>liter per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.4" spread="33.926"/>
                    <measurement group_id="O2" value="65.70" spread="30.500"/>
                    <measurement group_id="O3" value="60.87" spread="16.936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vz/F) of Crizotinib</title>
        <description>Vz/F of crizotinib is obtained from a Dose / (AUCinf *kel).
Kel = terminal phase elimination rate constant</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) of Crizotinib</title>
          <description>Vz/F of crizotinib is obtained from a Dose / (AUCinf *kel).
Kel = terminal phase elimination rate constant</description>
          <units>Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6170" spread="2843.7"/>
                    <measurement group_id="O2" value="2811" spread="1765.0"/>
                    <measurement group_id="O3" value="2545" spread="958.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Normalized AUC(0-inf) of Crizotinib</title>
        <description>Dose normalized (to 150 mg dose) AUC(0-inf) is obtained from AUC(0-inf) / (Dose/150).</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized AUC(0-inf) of Crizotinib</title>
          <description>Dose normalized (to 150 mg dose) AUC(0-inf) is obtained from AUC(0-inf) / (Dose/150).</description>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1423" spread="471.52"/>
                    <measurement group_id="O2" value="2284" spread="787.92"/>
                    <measurement group_id="O3" value="2463" spread="786.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Normalized AUClast of Crizotinib</title>
        <description>Dose normalized (to 150 mg dose) AUClast is obtained from AUClast / (Dose/150).</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized AUClast of Crizotinib</title>
          <description>Dose normalized (to 150 mg dose) AUClast is obtained from AUClast / (Dose/150).</description>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1339" spread="472.66"/>
                    <measurement group_id="O2" value="2239" spread="787.45"/>
                    <measurement group_id="O3" value="2395" spread="781.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Normalized Cmax of Crizotinib</title>
        <description>Dose normalized (to 150 mg dose) Cmax is obtained from Cmax / (Dose/150).</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Cmax of Crizotinib</title>
          <description>Dose normalized (to 150 mg dose) Cmax is obtained from Cmax / (Dose/150).</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.54" spread="25.570"/>
                    <measurement group_id="O2" value="93.36" spread="30.416"/>
                    <measurement group_id="O3" value="88.41" spread="22.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUC0-inf) of Plasma Active Metabolite (PF-06260182)</title>
        <description>AUC(0-inf) of PF-06260182 is estimated from the PF-06260182 concentration. It is obtained from AUClast plus (Clast/kel).
AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration.
Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUC0-inf) of Plasma Active Metabolite (PF-06260182)</title>
          <description>AUC(0-inf) of PF-06260182 is estimated from the PF-06260182 concentration. It is obtained from AUClast plus (Clast/kel).
AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration.
Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.</description>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.8" spread="99.369"/>
                    <measurement group_id="O2" value="535.8" spread="274.23"/>
                    <measurement group_id="O3" value="1046" spread="549.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Plasma Active Metabolite (PF-06260182)</title>
        <description>AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Plasma Active Metabolite (PF-06260182)</title>
          <description>AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.</description>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.1" spread="81.706"/>
                    <measurement group_id="O2" value="527.2" spread="273.68"/>
                    <measurement group_id="O3" value="1034" spread="547.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Plasma Active Metabolite (PF-06260182)</title>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Plasma Active Metabolite (PF-06260182)</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.24" spread="6.2371"/>
                    <measurement group_id="O2" value="37.63" spread="18.372"/>
                    <measurement group_id="O3" value="54.94" spread="14.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Cmax (Tmax) of Plasma Active Metabolite (PF-06260182)</title>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) of Plasma Active Metabolite (PF-06260182)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="5.00" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="6.00" lower_limit="5.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metabolite to Parent Ratio AUC(0-inf)</title>
        <description>The metabolic ratio (MR) is calculated by first converting the AUC(0-inf) for both crizotinib and metabolite (PF-06260182) from mass units to molar units.</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolite to Parent Ratio AUC(0-inf)</title>
          <description>The metabolic ratio (MR) is calculated by first converting the AUC(0-inf) for both crizotinib and metabolite (PF-06260182) from mass units to molar units.</description>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1261" spread="0.0200"/>
                    <measurement group_id="O2" value="0.1365" spread="0.0272"/>
                    <measurement group_id="O3" value="0.1544" spread="0.0343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metabolite to Parent Ratio AUClast</title>
        <description>The metabolic ratio (MR) is calculated by first converting the AUClast for both crizotinib and metabolite (PF-06260182) from mass units to molar units.</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolite to Parent Ratio AUClast</title>
          <description>The metabolic ratio (MR) is calculated by first converting the AUClast for both crizotinib and metabolite (PF-06260182) from mass units to molar units.</description>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1362" spread="0.0262"/>
                    <measurement group_id="O2" value="0.1370" spread="0.0272"/>
                    <measurement group_id="O3" value="0.1571" spread="0.0347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metabolite to Parent Ratio Cmax</title>
        <description>The metabolic ratio (MR) is calculated by first converting the Cmax for both crizotinib and metabolite (PF-06260182) from mass units to molar units.</description>
        <time_frame>0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crizotinib 150 mg</title>
            <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
          </group>
          <group group_id="O2">
            <title>Crizotinib 250 mg</title>
            <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
          </group>
          <group group_id="O3">
            <title>Crizotinib 400 mg</title>
            <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolite to Parent Ratio Cmax</title>
          <description>The metabolic ratio (MR) is calculated by first converting the Cmax for both crizotinib and metabolite (PF-06260182) from mass units to molar units.</description>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2371" spread="0.0833"/>
                    <measurement group_id="O2" value="0.2346" spread="0.0441"/>
                    <measurement group_id="O3" value="0.2260" spread="0.0429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For serious adverse event, up to 28 days after the last administration of the study drugs</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Crizotinib 150 mg</title>
          <description>A 150 mg single dose of crizotinib administered as one 50 mg Immediate Release Tablet (IRT) and one 100 mg IRT</description>
        </group>
        <group group_id="E2">
          <title>Crizotinib 250 mg</title>
          <description>A 250 mg single dose of crizotinib administered as one 50 mg IRT and two 100 mg IRTs</description>
        </group>
        <group group_id="E3">
          <title>Crizotinib 400 mg</title>
          <description>A 400 mg single dose of crizotinib administered as four 100 mg IRTs.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

